Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies

Journal of Chemical Information and Modeling

Volumn 51, Issue 8, 2011, Pages 1986-1998

  Felts, Anthony K ^a   Labarge, Krystal ^a   Bauman, Joseph D ^a,b   Patel, Dishaben V ^a,b   Himmel, Daniel M ^a,b   Arnold, Eddy ^a,b   Parniak, Michael A ^a   Levy, Ronald M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; ENZYME INHIBITION;

ACTIVE COMPOUNDS; COMPARATIVE ANALYSIS; COMPUTATIONAL STUDIES; HIV-1 REVERSE TRANSCRIPTASE; NATURAL PRODUCTS; POTENTIAL BINDING SITES; PUTATIVE BINDING SITES; RNA SUBSTRATE;

BINDING SITES;

GLUTAMINE; HYDRAZINE DERIVATIVE; HYDRAZONE DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SIMULATION; DRUG EFFECT; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; RECEIVER OPERATING CHARACTERISTIC; VIROLOGY;

ALLOSTERIC SITE; BINDING SITES; CATALYTIC DOMAIN; COMPUTER SIMULATION; GLUTAMINE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; HYDRAZINES; HYDRAZONES; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H; ROC CURVE; SMALL MOLECULE LIBRARIES;

EID: 80051975966     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci200194w     Document Type: Article

References (71)

1. Ruppert, J.; Welch, W.; Jain, A. N. Automatic identification and representation of protein binding sites for molecular docking Protein Sci. 1997, 6, 524-533 (Pubitemid 27120049)
2. Dennis, S.; Kortvelyesi, T.; Vajda, S. Computational mapping identifies the binding sites of organic solvents on proteins Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 4290-4295 (Pubitemid 34285978)
3. Kortvelyesi, T.; Silberstein, M.; Dennis, S.; Vajda, S. Improved mapping of protein binding sites. J. Comput.-Aided Mol. Des. 17, 17, 173-186.
4. Nayal, M.; Honig, B. On the nature of cavities on protein surfaces: Aapplication to the identification of drug-binding sites Proteins: Struct. Funct. Bioinf. 2006, 63, 892-906 (Pubitemid 43765141)
5. Coleman, R. G.; Salzberg, A. C.; Cheng, A. C. Structure-based identification of small molecule binding sites using a free energy model J. Chem. Inf. Model 2006, 46, 2631-2637 (Pubitemid 46008133)
6. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability Nat. Biotechnol. 2007, 25, 71-75 (Pubitemid 46087905)
7. Halgren, T. New method for fast and accurate binding-site identification and analysis Chem. Biol. Drug Des. 2007, 69, 146-148 (Pubitemid 46457523)
8. Halgren, T. A. Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 2009, 49, 377-389
9. Huang, N.; Jacobson, M. P. Binding-site assessment by virtual fragment screening PLoS One 2010, 5, e10109
10. Klumpp, K.; Mirzadegan, T. Recent progress in the design of small molecule inhibitors of HIV RNase H Curr. Pharm. Des. 2006, 12, 1909-1922
11. Jochmans, D. Novel HIV-1 reverse transcriptase inhibitors Virus Res. 2008, 134, 171-185
12. Yu, F.; Liu, X.; Zhan, P.; DeClercq, E. Recent advances in the research of HIV-1 RNase H inhibitors Mini-Rev. Med. Chem. 2008, 8, 1243-1251
13. Beilhartz, G. L.; Götte, M. HIV-1 ribonuclease H: Structure, catalytic mechanism and inhibitors Viruses 2010, 2, 900-926
14. Parniak, M. A.; Min, K.; Budihas, S. R.; Le Grice, S. F. J.; Beutler, J. A. A fluorescence-based high-throughput screening assay for inhibitors of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H activity Anal. Biochem. 2003, 322, 33-39 (Pubitemid 37188553)
15. Himmel, D. M.; Sarafianos, S. G.; Dharmasena, S.; Hossain, M. M.; McCoy-Simandle, K.; Ilina, T.; Clark, A. D., Jr.; Knight, J. L.; Julias, J. G.; Clark, P. K.; Krogh-Jespersen, K.; Levy, R. M.; Hughes, S. H.; Parniak, M. A.; Arnold, E. HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at novel site ACS Chem. Biol. 2006, 1, 702-712
16. Wendeler, M.; Lee, H.-F.; Bermingham, A.; Miller, J. T.; Chertov, O.; Bona, M. K.; Baichoo, N. S.; Ehteshami, M.; Beutler, J.; O'Keefe, B. R.; Götte, M.; Kvaratskhelia, M.; Le Grice, S. Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity ACS Chem. Biol. 2008, 3, 635-644
17. Gong, Q.; Menon, L.; Ilina, T.; Miller, L. G.; Ahn, J.; Parniak, M. A.; Ishima, R. Interaction of HIV-1 reverse transcriptase ribonuclease H with an acylhydrazone inhibitor Chem. Biol. Drug Des. 2011, 77, 39-47
18. Zhou, Z.; Felts, A. K.; Friesner, R. A.; Levy, R. M. Comparative performance of several flexible docking programs and scoring functions: Enrichment studies for a diverse set of pharmaceutically relevant targets J. Chem. Inf. Model. 2007, 47, 1599-1608 (Pubitemid 47210063)
19. Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: Where do we stand and where do we go? J. Med. Chem. 2010, 53, 521-538
20. di Marzo Veronese, F.; Copeland, T. D.; DeVico, A. L.; Rahman, R.; Oroszlan, S.; Gallo, R. C.; Sarngadharan, M. G. Characterization of highly immunogenic p66/p51 as reverse transcriptase of HTLV-III/LAV Science 1986, 231, 1289-1291 (Pubitemid 16036733)
21. Sarafianos, S. G.; Marchand, B.; Das, K.; Himmel, D. M.; Parniak, M. A.; Hughes, S. H.; Arnold, E. Structure and function of HIV-1 reverse transcriptase: Molecular mechanisms of polymerization and inhibition J. Mol. Biol. 2009, 385, 693-713
22. Tan, C.-K.; Civil, R.; Mian, A. M.; So, A. G.; Downey, K. M. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate Biochemistry 1991, 30, 4831-4835
23. Zhan, X.; Tan, C.-K.; Scott, W. A.; Mian, A. M.; Downey, K. M.; So, A. G. Catalytically distinct conformations of the ribonuclease H of HIV-1 reverse transcriptase by substrate cleavage patterns and inhibition by azidothymidylate and N -ethylmaleimide Biochemistry 1994, 33, 1366-1372 (Pubitemid 24093682)
24. Allen, S. J. W.; Krawczyk, S. H.; McGee, L. R.; Bischofberger, N.; Lulato, A. S.; Cherrington, J. M. Inhibition of HIV-1 RNase H activity by nucleotide dimers and monomers Antiviral Chem. Chemother. 1996, 7, 37-45 (Pubitemid 26029945)
25. Shaw-Reid, C. A.; Munshi, V.; Graham, P.; Wolfe, A.; Witmer, M.; Danzeisen, R.; Olsen, D. B.; Carroll, S. S.; Embrey, M.; Wai, J. S.; Miller, M. D.; Cole, J. L.; Hazuda, D. J. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(bezoylamino)thien-2-yl]-2,4-dioxobutanoic acid J. Biol. Chem. 2003, 278, 2777-2780 (Pubitemid 36801178)
26. Shaw-Reid, C. A.; Feuston, B.; Munshi, V.; Getty, K.; Krueger, J.; Hazuda, D. J.; Parniak, M. A.; Miller, M. D.; Lewis, D. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities Biochemistry 2005, 44, 1595-1606 (Pubitemid 40204402)
27. Tramontano, E.; Esposito, F.; Badas, R.; Di Santo, R.; Costi, R.; La Colla, P. L. 6-[1-(4-Fluorophenyl)methyl-1 H -pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro Antiviral Res. 2005, 65, 117-124 (Pubitemid 40222288)
28. Hang, J. Q.; Rajendran, S.; Yang, Y.; Li, Y.; In, P. W. K.; Overton, H.; Parkes, K. E. B.; Cammack, N.; Martin, J. A.; Klumpp, K. Activity of the isolated HIV RNase H domain and specific inhibition of N -hydroxyimides Biochem. Biophys. Res. Commun. 2004, 317, 321-329 (Pubitemid 38452485)
29. Budihas, S. R.; Gorshkova, I.; Gaidamakov, S.; Wamiru, A.; Bona, M. K.; Parniak, M. A.; Crouch, R. J.; McMahon, J. B.; Beutler, J. A.; Le Grice, S. F. J. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones Nucleic Acids Res. 2005, 33, 1249-1256 (Pubitemid 41439918)
30. Didierjean, J.; Isel, C.; Querré, F.; Mouscadet, J.-F.; Aubertin, A.-M.; Valnot, J.-Y.; Piettre, S. R.; Marquet, R. Inhibition of human immunodificiency virus type 1 reverse transcriptase, RNase H, and integrase activities by hydroxytropolones Antimicrob. Agents Chemother. 2005, 49, 4884-4894 (Pubitemid 41778898)
31. Beilhartz, G. L.; Wendeler, M.; Baichoo, N.; Rausch, J.; Le Grice, S.; Götte, M. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: Implications for RNase H inhibition J. Mol. Biol. 2009, 388, 462-474
32. Himmel, D. M.; Maegley, K. A.; Pauly, T. A.; Bauman, J. D.; Das, K.; Dharia, C.; Clark, A. D., Jr.; Ryan, K.; Hickey, M. J.; Love, R. A.; Hughes, S. H.; Bergqvist, S.; Arnold, E. Structure of HIV-1 reverse transcriptase with the inhibitor β-thujaplicinol bound at the RNase H active site Structure 2009, 17, 1625-1635
33. Billamboz, M.; Bailly, F.; Barreca, M. L.; De Luca, L.; Mouscadet, J.-F.; Calmels, C.; Andréola, M.-L.; Witvrouw, M.; Christ, F.; Debyser, Z.; Cotelle, P. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2 H,4 H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain J. Med. Chem. 2008, 51, 7717-7730
34. Kirschberg, T. A.; Balakrishnan, M.; Squires, N. H.; Barnes, T.; Brendza, K. M.; Chen, X.; Eisenberg, E. J.; Jin, W.; Kutty, N.; Leavitt, S.; Liclican, A.; Liu, Q.; Liu, X.; Mak, J.; Perry, J. K.; Wang, M.; Watkins, W. J.; Lansdon, E. B. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: Design, biochemical activity, and structural information J. Med. Chem. 2009, 52, 5781-5784
35. Su, H.-P.; Yan, Y.; Prasad, G. S.; Smith, R. F.; Daniels, C. L.; Abeywickrema, P. D.; Reid, J. C.; Loughran, H. M.; Kornienko, M.; Sharma, S.; Grobler, J. A.; Xu, B.; Sardana, V.; Allison, T. J.; Williams, P. D.; Darke, P. L.; Hazuda, D. J.; Munshi, S. Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors J. Virol. 2010, 84, 7625-7633
36. Loya, S.; Hizi, A. The inhibition of human immunodeficiency virus type 1 reverse transcriptase by avarol and avarone derivatives FEBS Lett. 1990, 269, 131-134 (Pubitemid 20245335)
37. Loya, S.; Tal, R.; Kashman, Y.; Hizi, A. Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 1990, 34, 2009-2012 (Pubitemid 20290304)
38. Loya, S.; Hizi, A. The interaction of illimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptase of human immunodeficiency and murine leukemia retroviruses J. Biol. Chem. 1993, 268, 9323-9328 (Pubitemid 23145978)
39. Min, B.-S.; Miyashiro, H.; Hattori, M. Inhibitory effects of quinones on RNase H activity associated with HIV-1 reverse transcriptase Phytother. Res. 2002, 16, S57-S62
40. Borkow, G.; Fletcher, R. S.; Barnard, J.; Arion, D.; Motakis, D.; Dmitrienko, G. I.; Parniak, M. A. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N -(4- tert -butylbenzoyl)-2-hydroxy-1-naphthaldehyde Biochemistry 1997, 36, 3179-3185 (Pubitemid 27142389)
41. Arion, D.; Sluis-Cremer, N.; Min, K.-L.; Abram, M. E.; Fletcher, R. S.; Parniak, M. A. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase J. Biol. Chem. 2002, 277, 1370-1374
42. Sluis-Cremer, N.; Arion, D.; Parniak, M. A. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N -acyl hydrazone inhibitors Mol. Pharmacol. 2002, 62, 398-405 (Pubitemid 34804120)
43. Di Grandi, M.; Olson, M.; Prashad, A. S.; Bebernitz, G.; Luckay, A.; Mullen, S.; Hu, Y.; Krishnamurthy, G.; Pitts, K.; O'Connell, J. Small molecule inhibitors of HIV RT ribonuclease H Bioorg. Med. Chem. Lett. 2010, 20, 398-402
44. Nowotny, M.; Gaidamakov, S. A.; Ghirland, R.; Cerritelli, S. M.; Crouch, R. J.; Yang, W. Structure of human RNase H1 complexed with an RNA/DNA hybrid: Insight into HIV reverse transcription Mol. Cell 2007, 28, 264-276 (Pubitemid 47599996)
45. Henrich, S.; Salo-Ahen, O. M. H.; Huang, B.; Rippman, F. F.; Cruciani, G.; Wade, R. C. Computational approaches to identifying and characterizing protein binding sites for ligand design J. Mol. Recogn. 2010, 23, 209-219
46. Zweig, M. H.; Campbell, G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine Clin. Chem. 1993, 39, 561-577 (Pubitemid 23118304)
47. Triballeau, N.; Acher, F.; Brabet, I.; Pin, J.-P.; Bertrand, H.-O. Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4 J. Med. Chem. 2005, 48, 2534-2547 (Pubitemid 40520517)
48. Perola, E.; Walters, W. P.; Charifson, P. S. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance Proteins: Struct. Funct. Bioinf. 2004, 56, 235-249 (Pubitemid 38850158)
49. Kontoyianni, M.; Sokol, G. S.; McClellan, L. M. Evaluation of library ranking efficacy in virtual screening J. Comput. Chem. 2005, 26, 11-22 (Pubitemid 40021619)
50. Cummings, M. D.; DesJarlais, R. L.; Gibbs, A. C.; Mohan, V.; Jaeger, E. P. Comparison of automated docking programs as virtual screening tools J. Med. Chem. 2005, 48, 962-976 (Pubitemid 40270442)
51. Warren, G. L.; Andrews, C. W.; Capelli, A.-M.; Clarke, B.; J., L.; Lambert, M. H.; Lindvall, M.; Nevins, N.; Semus, S. F.; Senger, S.; Tedesco, G.; Wall, I. D.; Woolven, J. M.; Peishoff, C. E.; Head, M. S. A critical assessment of docking programs and scoring functions J. Med. Chem. 2006, 49, 5912-5931 (Pubitemid 44484938)
52. Cross, J. B.; Thompson, D. C.; Rai, B. K.; Baber, J. C.; Fan, K. Y.; Hu, Y.; Humblet, C. Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy J. Chem. Inf. Model. 2009, 49, 1455-1474
53. Irwin, J. J.; Shoichet, B. K.; Mysinger, M. M.; Huang, N.; Colizzi, F.; Wassam, P.; Cao, Y. Automated docking screens: A feasibility study J. Med. Chem. 2009, 52, 5712-5720
54. Leach, A. R.; Shoichet, B. K.; Peishoff, C. E. Docking and scoring J. Med. Chem. 2006, 49, 5851-5855
55. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure fro protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196 (Pubitemid 44595196)
56. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids J. Am. Chem. Soc. 1996, 118, 11225-11236 (Pubitemid 26399746)
57. Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. L. Evaluation and reparameterization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 2001, 105, 6474-6487 (Pubitemid 35339015)
58. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions. 1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes J. Comput.-Aided Mol. Des. 1997, 11, 425-445 (Pubitemid 127505895)
59. Feng, B. Y.; Simeonov, A.; Jadhav, A.; Babaoglu, K.; Inglese, J.; Shoichet, B. K.; Austin, C. P. A high-throughput screen for aggregation-based inhibition in a large compound library J. Med. Chem. 2007, 50, 2385-2390 (Pubitemid 46799249)
60. Nicholls, A. What do we know and when do we know it? J. Comput.-Aided Mol. Des. 2008, 22, 239-255
61. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank Nucleic Acids Res. 2000, 28, 235-242 (Pubitemid 30047768)
62. Sarafianos, S. G.; Das, K.; Tantillo, C.; D., C., A.; Ding, J.; Whitcomb, J. M.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA EMBO J. 2001, 20, 1449-1461 (Pubitemid 32233984)
63. Banks, J. L.; Beard, H. S.; Cao, Y.; Cho, A. E.; Damm, W.; Farid, R.; Felts, A. K.; Halgren, T. A.; Mainz, D. T.; Maple, J. R.; Murphy, R.; Philipp, D. M.; Repasky, M. P.; Zhang, L. Y.; Berne, B. J.; Friesner, R. A.; Gallicchio, E.; Levy, R. M. Integrated modeling program, applied chemical theory (IMPACT) J. Comput. Chem. 2005, 26, 1752-1780 (Pubitemid 43076184)
64. Fukunishi, Y.; Nakamura, H. Prediction of ligand-binding sites of proteins by molecular docking calculation for a random ligand library Protein Sci. 2011, 20, 95-106
65. Dixon, S. K.; Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, D. E.; Friesner, R. A. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results J. Comput.-Aided Mol. Des. 2006, 20, 647-671 (Pubitemid 46023928)
66. Johnson, S. R. The trouble with QSAR (or how I learned to stop worrying and embrace fallacy) J. Chem. Inf. Model. 2008, 48, 25-26 (Pubitemid 351271047)
67. Manchester, J.; Czerminski, R. Caution: Popular "benchmark" data sets do not distinguish the merits of 3D QSAR methods J. Chem. Inf. Model. 2009, 49, 1449-1454
68. Leach, A. R.; Gillet, V. J.; Lewis, R. A.; Taylor, R. Three-dimensional pharmacophore methods in drug discovery J. Med. Chem. 2010, 53, 539-558
69. Seco, J.; Luque, J.; Barril, X. Binding site detection and druggability index from first principles J. Med. Chem. 2009, 52, 2363-2371
70. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics J. Mol. Graphics 1996, 14, 33-38 (Pubitemid 26152973)
71. R: A Language and Environment for Statistical Computing, version 2.11.1; R Foundation for Statistical Computing: Vienna, Austria, 2010.